Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Transcode Therapeutics, Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this matter is assigned to 1 distinct examiner, reflecting a singular focus for the company's current patent office interactions. This activity is restricted to 1 distinct art unit, which centralizes the technical examination within a specific regulatory framework. This focused environment allows the company to develop a deep understanding of the specific requirements for this art unit.
BROWE, DAVID is the busiest examiner for the company, currently handling 1 pending office action. Since the total number of 1 pending office action for the portfolio is assigned to this individual, this examiner is responsible for the company's entire active prosecution pipeline. This concentration allows for a highly targeted approach to addressing examiner concerns and navigating the specific requirements of the assigned art unit. The company can focus its efforts on the specific feedback provided by this examiner to move the application toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CABRAL, ROBERT S | 1 | 62.7% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | CABRAL, ROBERT S | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | CABRAL, ROBERT S | 12d |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | CABRAL, ROBERT S | 1614 | §102§103§112Other | Non-Final OA | 12d | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTranscode Therapeutics, Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Robert S Cabral has the most, with 1 of Transcode Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.